Deciphering the mechanism of HM43239 inhibiting the mutant F691L resistant to gilteritinib in FMS-like tyrosine kinase 3

References

• Abu-Duhier, F. M., Goodeve, A. C., Wilson, G. A., Care, R. S., Peake, I. R., & Reilly, J. T. (2001). Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. British Journal of Haematology, 113(4), 983–988. https://doi.org/10.1046/j.1365-2141.2001.02850.x
   PubMed Web of Science ®Google Scholar
• Bae, I., Choi, J., Song, J., Byun, J.-Y., Lee, E., Song, T., Kim, Y.-Y., Bak, Y., Kim, Y. H., Ahn, Y. G., & Suh, K. H. (2021). Abstract 1257: HM43239, a novel FLT3 inhibitor, has the potential to inhibit mutations resistant to FLT3 inhibitors. Cancer Research, 81(13_Supplement), 1257–1257. https://doi.org/10.1158/1538-7445.AM2021-1257
   Web of Science ®Google Scholar
• Berenstein, R. (2015). Class III receptor tyrosine kinases in acute leukemia – biological functions and modern laboratory analysis. Biomarker Insights, 10(Suppl 3), 1–14. https://doi.org/10.4137/bmi.S22433
   PubMedGoogle Scholar
• Breitenbuecher, F., Schnittger, S., Grundler, R., Markova, B., Carius, B., Brecht, A., Duyster, J., Haferlach, T., Huber, C., & Fischer, T. (2009). Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood, 113(17), 4074–4077. https://doi.org/10.1182/blood-2007-11-125476
   PubMed Web of Science ®Google Scholar
• Butowski, N., Colman, H., De Groot, J. F., Omuro, A. M., Nayak, L., Wen, P. Y., Cloughesy, T. F., Marimuthu, A., Haidar, S., Perry, A., Huse, J., Phillips, J., West, B. L., Nolop, K. B., Hsu, H. H., Ligon, K. L., Molinaro, A. M., & Prados, M. (2016). Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-oncology, 18(4), 557–564. https://doi.org/10.1093/neuonc/nov245
   PubMed Web of Science ®Google Scholar
• Cortes, J. E., Khaled, S., Martinelli, G., Perl, A. E., Ganguly, S., Russell, N., Krämer, A., Dombret, H., Hogge, D., Jonas, B. A., Leung, A. Y.-H., Mehta, P., Montesinos, P., Radsak, M., Sica, S., Arunachalam, M., Holmes, M., Kobayashi, K., Namuyinga, R., … Levis, M. J. (2019). Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A multicentre, randomised, controlled, open-label, phase 3 trial. The Lancet. Oncology, 20(7), 984–997. https://doi.org/10.1016/s1470-2045(19)30150-0
   PubMed Web of Science ®Google Scholar
• Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., Lehrnbecher, T., Leverger, G., Mejstrikova, E., Meshinchi, S., Pession, A., Raimondi, S. C., Sung, L., Stary, J., Zwaan, C. M., Kaspers, G. J. L., & Reinhardt, D., AML Committee of the International BFM Study Group. (2012). Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood, 120(16), 3187–3205. https://doi.org/10.1182/blood-2012-03-362608
   PubMed Web of Science ®Google Scholar
• Daver, N., Lee, K. H., Jung, C. W., Soo, Y. S., Arellano, M. L., Jonas, B. A., Yoon, J., Jung, S., Noh, Y. S., Bae, I., & Kim, S. (2020). HM43239, a novel small molecule inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like tyrosine kinase 3 (FLT3) mutations: Phase 1/2 study. Blood, 136(Supplement 1), 1. https://doi.org/10.1182/blood-2020-143244
   PubMedGoogle Scholar
• Daver, N., Lee, K. H., Jung, C. W., Yoon, S.-S., Arellano, M. L., Yoon, J., Lee, N., Kim, H., Lee, J., Jonas, B. A., & Baek, S. (2021). First in Human (FIH) FLT3 and SYK inhibitor HM43239 shows single agent activity in patients (pts) with relapsed or refractory (R/R) FLT3 mutated and wild-type acute myeloid leukemia (AML). Blood, 138(Supplement 1), 702. https://doi.org/10.1182/blood-2021-150014
   Google Scholar
• Daver, N. G., Lee, K. H., Yoon, S.-S., Jung, C. W., Kang, H. J., Jung, S., Seo, S., Yoon, J., Kim, H., Noh, Y. S., Seo, Y., Kwon, H., Han, O., Baek, S., Seo, K., & Suh, K. H. (2019). HM43239, a novel potent small molecule FLT3 inhibitor, in Acute Myeloid Leukemia (AML) with FMS-like Tyrosine Kinase 3 (FLT3) mutations: Phase 1/2 study. Blood, 134(Supplement_1), 1331–1331. https://doi.org/10.1182/blood-2019-129670
   Web of Science ®Google Scholar
• Gilliland, D. G., & Griffin, J. D. (2002). The roles of FLT3 in hematopoiesis and leukemia. Blood, 100(5), 1532–1542. https://doi.org/10.1182/blood-2002-02-0492
   PubMed Web of Science ®Google Scholar
• Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47(7), 1750–1759. https://doi.org/10.1021/jm030644s
   PubMed Web of Science ®Google Scholar
• Joshi, S. K., Sharzehi, S., Pittsenbarger, J., Bottomly, D., Tognon, C. E., McWeeney, S. K., Druker, B. J., & Traer, E. (2021). A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance. American Journal of Hematology, 96(7), E226–e229. https://doi.org/10.1002/ajh.26174
   PubMed Web of Science ®Google Scholar
• Kawase, T., Nakazawa, T., Eguchi, T., Tsuzuki, H., Ueno, Y., Amano, Y., Suzuki, T., Mori, M., & Yoshida, T. (2019). Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells. Oncotarget, 10(58), 6111–6123. https://doi.org/10.18632/oncotarget.27222
   PubMedGoogle Scholar
• Kayser, S., Schlenk, R. F., Londono, M. C., Breitenbuecher, F., Wittke, K., Du, J., Groner, S., Späth, D., Krauter, J., Ganser, A., Döhner, H., Fischer, T., & Döhner, K, German-Austrian AML Study Group (AMLSG). (2009). Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood, 114(12), 2386–2392. https://doi.org/10.1182/blood-2009-03-209999
   PubMed Web of Science ®Google Scholar
• Lee, L. Y., Hernandez, D., Rajkhowa, T., Smith, S. C., Raman, J. R., Nguyen, B., Small, D., & Levis, M. (2017). Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood, 129(2), 257–260. https://doi.org/10.1182/blood-2016-10-745133
   PubMed Web of Science ®Google Scholar
• Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. https://doi.org/10.1021/acs.jctc.5b00255
   PubMed Web of Science ®Google Scholar
• Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., Misawa, S. (1996). Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia, 10(12), 1911–1918.
   PubMed Web of Science ®Google Scholar
• O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Bhatt, V., Bixby, D., Blum, W., Coutre, S. E., De Lima, M., Fathi, A. T., Fiorella, M., Foran, J. M., Gore, S. D., Hall, A. C., Kropf, P., Lancet, J., Maness, L. J., … Ogba, N. (2017). Acute myeloid leukemia, Version 3.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 15(7), 926–957. https://doi.org/10.6004/jnccn.2017.0116
   PubMed Web of Science ®Google Scholar
• Pulte, E. D., Norsworthy, K. J., Wang, Y., Xu, Q., Qosa, H., Gudi, R., Przepiorka, D., Fu, W., Okusanya, O. O., Goldberg, K. B., De Claro, R. A., Farrell, A. T., & Pazdur, R. (2021). FDA approval summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 27(13), 3515–3521. https://doi.org/10.1158/1078-0432.Ccr-20-4271
   PubMed Web of Science ®Google Scholar
• Roos, K., Wu, C., Damm, W., Reboul, M., Stevenson, J. M., Lu, C., Dahlgren, M. K., Mondal, S., Chen, W., Wang, L., Abel, R., Friesner, R. A., & Harder, E. D. (2019). OPLS3e: Extending force field coverage for drug-like small molecules. Journal of Chemical Theory and Computation, 15(3), 1863–1874. https://doi.org/10.1021/acs.jctc.8b01026
   PubMed Web of Science ®Google Scholar
• Skjærven, L., Yao, X. Q., Scarabelli, G., & Grant, B. J. (2014). Integrating protein structural dynamics and evolutionary analysis with Bio3D. BMC Bioinformatics, 15(1), 399. https://doi.org/10.1186/s12859-014-0399-6
   PubMed Web of Science ®Google Scholar
• Smith, C. C., Zhang, C., Lin, K. C., Lasater, E. A., Zhang, Y., Massi, E., Damon, L. E., Pendleton, M., Bashir, A., Sebra, R., Perl, A., Kasarskis, A., Shellooe, R., Tsang, G., Carias, H., Powell, B., Burton, E. A., Matusow, B., Zhang, J., … Shah, N. P. (2015). Characterizing and overriding the structural mechanism of the quizartinib-resistant FLT3 "Gatekeeper" F691L mutation with PLX3397. Cancer Discovery, 5(6), 668–679. https://doi.org/10.1158/2159-8290.Cd-15-0060
   PubMed Web of Science ®Google Scholar
• Sun, M., Zhang, X., Gao, Z., Liu, T., Luo, C., Zhao, Y., Liu, Y., He, Z., Wang, J., & Sun, J. (2019). Probing a dipeptide-based supramolecular assembly as an efficient camptothecin delivering carrier for cancer therapy: Computational simulations and experimental validations. Nanoscale, 11(9), 3864–3876. https://doi.org/10.1039/c8nr07014h
   PubMed Web of Science ®Google Scholar
• Tarver, T. C., Hill, J. E., Rahmat, L., Perl, A. E., Bahceci, E., Mori, K., & Smith, C. C. (2020). Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Advances, 4(3), 514–524. https://doi.org/10.1182/bloodadvances.2019000919
   PubMed Web of Science ®Google Scholar
• Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004). Development and testing of a general amber force field. Journal of Computational Chemistry, 25(9), 1157–1174. https://doi.org/10.1002/jcc.20035
   PubMed Web of Science ®Google Scholar
• Williams, A. B., Nguyen, B., Li, L., Brown, P., Levis, M., Leahy, D., & Small, D. (2013). Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia, 27(1), 48–55. https://doi.org/10.1038/leu.2012.191
   PubMed Web of Science ®Google Scholar
• Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., Akiyama, H., Saito, K., Nishimura, M., Motoji, T., Shinagawa, K., Takeshita, A., Saito, H., Ueda, R., Ohno, R., & Naoe, T. (2001). Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood, 97(8), 2434–2439. https://doi.org/10.1182/blood.v97.8.2434
   PubMed Web of Science ®Google Scholar
• Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., Sprankle, K. G., Patel, H. K., Levis, M., Armstrong, R. C., James, J., & Bhagwat, S. S. (2009). AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood, 114(14), 2984–2992. https://doi.org/10.1182/blood-2009-05-222034
   PubMed Web of Science ®Google Scholar
• Zavorka Thomas, M. E., Lu, X., Talebi, Z., Jeon, J. Y., Buelow, D. R., Gibson, A. A., Uddin, M. E., Brinton, L. T., Nguyen, J., Collins, M., Lodi, A., Sweeney, S. R., Campbell, M. J., Sweet, D. H., Sparreboom, A., Lapalombella, R., Tiziani, S., & Baker, S. D. (2021). Gilteritinib inhibits glutamine uptake and utilization in FLT3-ITD-positive AML. Molecular Cancer Therapeutics, 20(11), 2207–2217. https://doi.org/10.1158/1535-7163.Mct-21-0071
   PubMed Web of Science ®Google Scholar
• Zorn, J. A., Wang, Q., Fujimura, E., Barros, T., & Kuriyan, J. (2015). Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PloS One, 10(4), e0121177. https://doi.org/10.1371/journal.pone.0121177
   PubMed Web of Science ®Google Scholar